Hills Bank & Trust Co. lowered its stake in Clorox Co (NYSE:CLX) by 4.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,870 shares of the company’s stock after selling 160 shares during the quarter. Hills Bank & Trust Co.’s holdings in Clorox were worth $587,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently modified their holdings of the company. First Trust Advisors LP boosted its position in shares of Clorox by 45.5% during the 1st quarter. First Trust Advisors LP now owns 315,484 shares of the company’s stock valued at $50,623,000 after acquiring an additional 98,676 shares during the last quarter. Marshall Wace North America L.P. bought a new stake in Clorox in the 1st quarter worth approximately $65,000. FMR LLC lifted its position in Clorox by 13.1% in the 1st quarter. FMR LLC now owns 597,756 shares of the company’s stock worth $95,915,000 after buying an additional 69,187 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in Clorox by 1.1% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 374,868 shares of the company’s stock worth $60,151,000 after buying an additional 4,194 shares during the last quarter. Finally, Thomasville National Bank lifted its position in Clorox by 9.2% in the 2nd quarter. Thomasville National Bank now owns 3,570 shares of the company’s stock worth $547,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 78.42% of the company’s stock.
A number of analysts recently weighed in on the company. ValuEngine downgraded Clorox from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Barclays set a $138.00 target price on Clorox and gave the stock a “sell” rating in a research report on Friday, November 1st. Credit Suisse Group dropped their target price on Clorox from $172.00 to $168.00 and set an “outperform” rating for the company in a research report on Thursday, October 3rd. UBS Group dropped their target price on Clorox from $128.00 to $125.00 and set a “sell” rating for the company in a research report on Thursday, October 3rd. Finally, JPMorgan Chase & Co. restated an “underweight” rating and issued a $137.00 target price (down previously from $143.00) on shares of Clorox in a research report on Thursday, October 3rd. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. Clorox presently has an average rating of “Hold” and a consensus price target of $152.00.
Clorox (NYSE:CLX) last posted its earnings results on Thursday, October 31st. The company reported $1.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.54 by $0.05. Clorox had a return on equity of 123.56% and a net margin of 13.20%. The firm had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.51 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. The business’s revenue was down 3.6% compared to the same quarter last year. As a group, research analysts expect that Clorox Co will post 6.16 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Wednesday, October 30th will be paid a dividend of $1.06 per share. The ex-dividend date is Tuesday, October 29th. This represents a $4.24 annualized dividend and a dividend yield of 2.86%. Clorox’s dividend payout ratio (DPR) is presently 67.09%.
In other Clorox news, SVP Michael R. Costello sold 6,997 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $162.56, for a total value of $1,137,432.32. Following the sale, the senior vice president now directly owns 29,016 shares of the company’s stock, valued at $4,716,840.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Andrew J. Mowery sold 5,648 shares of the business’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $146.29, for a total value of $826,245.92. Following the completion of the sale, the senior vice president now directly owns 15,920 shares in the company, valued at $2,328,936.80. The disclosure for this sale can be found here. Insiders have sold 15,870 shares of company stock worth $2,484,000 over the last three months. Insiders own 1.14% of the company’s stock.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.
Further Reading: Cost of Equity For A Business, Investors
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.